Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019027828) ANTI-IL-17 ANTIBODY DOSE REGIMEN
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/027828 International Application No.: PCT/US2018/044064
Publication Date: 07.02.2019 International Filing Date: 27.07.2018
IPC:
C07K 16/24 (2006.01) ,A61P 17/06 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17
Drugs for dermatological disorders
06
Antipsoriatics
Applicants:
ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, Indiana 46285, US
Inventors:
OSUNTOKUN, Olawale Olukayode; US
POLZER, Paula Kay; US
Agent:
MARKS, Duane C.; US
COMBS, Tonya L.; US
Priority Data:
62/541,24604.08.2017US
62/542,94009.08.2017US
62/554,75206.09.2017US
Title (EN) ANTI-IL-17 ANTIBODY DOSE REGIMEN
(FR) SCHÉMA POSOLOGIQUE D'ANTICORPS ANTI-IL-17
Abstract:
(EN) The present invention provides dose regimens for anti-IL-17 antibodies. These anti-IL-17 antibody dose regiments can be used to treat psoriasis, ankylosing spondilitis, rheumatoid arthritis, psoriatic arthritis or multiple myeloma.
(FR) La présente invention concerne des schémas posologiques d'anticorps anti-IL-17. Les schémas posologiques d'anticorps anti-IL-17 selon la présente invention peuvent être utilisés pour traiter le psoriasis, la spondylarthrite ankylosante, la polyarthrite rhumatoïde, l'arthrite psoriasique ou le myélome multiple.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)